We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Relief Therapeutics Holdings AG (QB) | USOTC:RLFFD | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.2038 | 0.00 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the Month of November, 2023
Commission File Number: 001-41174
RELIEF THERAPEUTICS Holding SA
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of registrant’s name into English)
Switzerland
(Jurisdiction of incorporation or organization)
Avenue de Sécheron 15
1202 Geneva
Switzerland
Tel: +41 22 545 11 16
(Address of principal executive offices)
Indicate by check mark if the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On November 22, 2023, Relief Therapeutics Holding SA (the “Company”) announced that its current Chief Executive Officer, Jack Weinstein, will be stepping down as part of a leadership transition, and that Michelle Lock, a highly experienced pharmaceutical executive and current independent member of the Company’s Board of Directors, will be assuming the role of CEO on an interim basis. On the same date, the Company issued a press release reporting the transition entitled “Relief Therapeutics Announces CEO Transition”. A copy of the press release is attached to this Form 6-K as Exhibit 99.1.
INDEX TO EXHIBITS
Exhibit No. | Description | |
99.1 | Press Release dated November 22, 2023. |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RELIEF THERAPEUTICS Holding SA
By: /s/ Jeremy Meinen
Jeremy Meinen
Chief Financial Officer
Dated: November 22, 2023
- 3 -
Exhibit 99.1
Ad hoc announcement pursuant to Art. 53 LR
Relief Therapeutics Announces CEO Transition
GENEVA (NOV. 22, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its current chief executive officer (CEO), Jack Weinstein, will be stepping down as part of a leadership transition. The company is pleased to announce that Michelle Lock, a highly experienced pharmaceutical executive and current independent member of Relief’s Board of Directors, will be assuming the role of CEO on an interim basis.
“Michelle has been an active and insightful member of our Board of Directors. Her deep understanding of our organization and her extensive leadership experience in both biotech and big pharma settings make her an ideal leader for Relief. We are excited to have Michelle continue on the Board of Directors and step in as our new CEO.” said Raghuram (Ram) Selvaraju, Chairman of the Board of Directors. “I want to extend our gratitude to Jack for his dedication and the important contributions he made over the years.” added Dr. Selvaraju.
Ms. Lock previously held executive roles as chief operating officer of Covis Pharma Group and senior vice president and head of Europe and International at Acceleron Pharma Inc. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience and spent 24 years with Bristol-Myers Squibb. Her appointment as interim CEO of Relief is effective immediately.
In response to her appointment, Ms. Lock commented, “I am honored to step into the role of CEO of Relief. This company has a strong legacy of bringing significant value to patients, and I am excited to lead our talented team as we continue to advance our pipeline. I am committed to driving our company on a path of innovation and enhanced patient impact.”
The Company is looking forward to a new chapter under Michelle Lock’s leadership.
ABOUT RELIEF THERAPEUTICS
Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics’ portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic™ and TEHCLO™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners. Relief Therapeutics’ mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Monza, Italy. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn and Twitter.
1 / 2
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief’s filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief Therapeutics. Copies of Relief Therapeutics’ filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief Therapeutics does not undertake any obligation to update the information contained herein, which speaks only as of this date.
2 / 2
1 Year Relief Therapeutics (QB) Chart |
1 Month Relief Therapeutics (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions